Merck partner NewLink grabs up to $76M in Ebola vax funding from feds - FiercePharma

FiercePharma
Merck partner NewLink grabs up to $76M in Ebola vax funding from feds
FiercePharma
On the heels of crushing Phase III results for its pancreatic cancer candidate, NewLink Genetics has won a lifeline from the U.S. government. The biotech nabbed up to $76 million in BARDA funding to advance its Merck-licensed Ebola vaccine. Through an ...